These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38331350)

  • 21. High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in Triple-Negative Breast Cancer.
    Rokudai S
    Methods Mol Biol; 2020; 2108():297-303. PubMed ID: 31939190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
    Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
    Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
    Yi Z; Ma F; Rong G; Guan Y; Li C; Xu B
    Cancer Commun (Lond); 2020 Jun; 40(6):260-269. PubMed ID: 32436611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.
    Huang Y; Qiang Y; Jian L; Jin Z; Lang Q; Sheng C; Shichong Z; Cai C
    Acad Radiol; 2022 Dec; 29(12):e261-e270. PubMed ID: 35450798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres.
    Samassekou O; Bastien N; Lichtensztejn D; Yan J; Mai S; Drouin R
    Genes Chromosomes Cancer; 2014 Nov; 53(11):934-50. PubMed ID: 25059482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
    Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
    Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
    R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
    J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure - A computational approach.
    Balasundaram A; Kumar S U; D TK; Anil Dedge A; R G; K SS; R S; C GPD
    J Biomol Struct Dyn; 2023; 41(24):15584-15597. PubMed ID: 37011004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triptolide promotes degradation of the unfolded gain-of-function Tp53
    Zhou J; Luo J; Li P; Zhou Y; Li P; Wang F; Mallio CA; Rossi G; Jalal AH; Filipovic N; Tian Z; Zhao X
    Transl Lung Cancer Res; 2022 May; 11(5):802-816. PubMed ID: 35693277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct TP53 Mutation Types Exhibit Increased Sensitivity to Ferroptosis Independently of Changes in Iron Regulatory Protein Activity.
    Thompson LR; Oliveira TG; Hermann ER; Chowanadisai W; Clarke SL; Montgomery MR
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic triple-negative breast cancer patient with
    Meißner T; Mark A; Williams C; Berdel WE; Wiebe S; Kerkhoff A; Wardelmann E; Gaiser T; Müller-Tidow C; Rosenstiel P; Arnold N; Leyland-Jones B; Franke A; Stanulla M; Forster M
    Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
    Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
    Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.
    King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW
    Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.
    Bataillon G; Fuhrmann L; Girard E; Menet E; Laé M; Capovilla M; Treilleux I; Arnould L; Penault-Llorca F; Rouzier R; Marchiò C; Bieche I; Vincent-Salomon A
    Histopathology; 2018 Aug; 73(2):273-283. PubMed ID: 29537649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.
    Yi D; Xu L; Luo J; You X; Huang T; Zi Y; Li X; Wang R; Zhong Z; Tang X; Li A; Shi Y; Rao J; Zhang Y; Sang J
    Hum Genomics; 2019 Jan; 13(1):4. PubMed ID: 30630526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
    Bae SY; Nam SJ; Jung Y; Lee SB; Park BW; Lim W; Jung SH; Yang HW; Jung SP
    Breast Cancer Res Treat; 2018 Nov; 172(2):437-444. PubMed ID: 30132220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
    Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
    Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
    Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
    Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.